Reata Pharmaceuticals, Inc. - (RETA): Price and Financial Metrics

Reata Pharmaceuticals, Inc. - (RETA): $30.44

0.05 (+0.16%)

POWR Rating

Component Grades














  • Quality is the dimension where RETA ranks best; there it ranks ahead of 38.32% of US stocks.
  • The strongest trend for RETA is in Stability, which has been heading down over the past 179 days.
  • RETA's current lowest rank is in the Momentum metric (where it is better than 8.18% of US stocks).

RETA Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for RETA is 0.06 -- better than merely 10.23% of US stocks.
  • RETA's price/sales ratio is 109.43; that's higher than the P/S ratio of 97.75% of US stocks.
  • In terms of volatility of its share price, RETA is more volatile than 98.06% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Reata Pharmaceuticals Inc are FREQ, SAGE, TBPH, BLUE, and AKTS.
  • Visit RETA's SEC page to see the company's official filings. To visit the company's web site, go to

RETA Valuation Summary

  • In comparison to the median Healthcare stock, RETA's EV/EBIT ratio is 147.78% lower, now standing at -14.
  • Over the past 64 months, RETA's price/sales ratio has gone up 494.4.
  • RETA's price/earnings ratio has moved up 166 over the prior 64 months.

Below are key valuation metrics over time for RETA.

Stock Date P/S P/B P/E EV/EBIT
RETA 2021-08-31 499.6 12.3 -14.3 -14.0
RETA 2021-08-30 496.4 12.3 -14.2 -13.9
RETA 2021-08-27 507.7 12.6 -14.5 -14.2
RETA 2021-08-26 489.1 12.1 -14.0 -13.6
RETA 2021-08-25 505.8 12.5 -14.5 -14.2
RETA 2021-08-24 496.6 12.3 -14.2 -13.9

RETA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RETA has a Quality Grade of C, ranking ahead of 31.15% of graded US stocks.
  • RETA's asset turnover comes in at 0.01 -- ranking 391st of 682 Pharmaceutical Products stocks.
  • INVA, SUPN, and LUMO are the stocks whose asset turnover ratios are most correlated with RETA.

The table below shows RETA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.010 1 3.336
2021-03-31 0.012 1 4.920
2020-12-31 0.013 1 8.823
2020-09-30 0.013 1 34.641
2020-06-30 0.027 1 271.349
2020-03-31 0.042 1 -40.289

RETA Price Target

For more insight on analysts targets of RETA, see our RETA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $226.44 Average Broker Recommendation 1.17 (Strong Buy)

RETA Stock Price Chart Interactive Chart >

Price chart for RETA

RETA Price/Volume Stats

Current price $30.44 52-week high $144.70
Prev. close $30.39 52-week low $20.24
Day low $29.60 Volume 237,400
Day high $30.76 Avg. volume 612,520
50-day MA $28.72 Dividend yield N/A
200-day MA $49.45 Market Cap 1.11B

Reata Pharmaceuticals, Inc. - (RETA) Company Bio

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company was founded in 2002 and is based in Irving, Texas.

RETA Latest News Stream

Event/Time News Detail
Loading, please wait...

RETA Latest Social Stream

Loading social stream, please wait...

View Full RETA Social Stream

Latest RETA News From Around the Web

Below are the latest news stories about Reata Pharmaceuticals Inc that investors may wish to consider to help them evaluate RETA as an investment opportunity.

Reata slips as FDA rejects kidney disease therapy

Reata Pharmaceuticals (NASDAQ:RETA) has lost ~4% in the post-market Friday after the company announced that the U.S. Food and Drug Administration (“FDA”) issued a Complete Response Letter (CRL) regarding its New Drug Application (“NDA”) for bardoxolone methyl (“bardoxolone”). With its NDA, the clinical-stage biopharmaceutical company had sought the U.S. regulatory clearance for...

Seeking Alpha | February 26, 2022

Reata Pharmaceuticals Receives Complete Response Letter From The FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome

PLANO, Texas, February 25, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," or "we"), today announced that the U.S. Food and Drug Administration ("FDA") has issued a Complete Response Letter ("CRL") regarding the New Drug Application ("NDA") for bardoxolone methyl ("bardoxolone") for the treatment of patients with chronic kidney disease ("CKD") caused by Alport syndrome.

Yahoo | February 25, 2022

Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q4 Earnings Expected to Decline

Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 21, 2022

Reata Pharmaceuticals, Inc. To Report Fourth Quarter and Full Year 2021 Financial Results and To Provide an Update on Development Programs on February 28, 2022

PLANO, Texas, February 18, 2022--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on the Company’s business operations and clinical development programs pre-market on February 28, 2022.

Yahoo | February 18, 2022

Biondo Investment Advisors, LLC Buys Unity Software Inc, Coinbase Global Inc, PNC Financial ...

Milford, PA, based Investment company Biondo Investment Advisors, LLC (Current Portfolio) buys Unity Software Inc, Coinbase Global Inc, PNC Financial Services Group Inc, sells Intuitive Surgical Inc, Reata Pharmaceuticals Inc, Teladoc Health Inc, Align Technology Inc, 10x Genomics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Biondo Investment Advisors, LLC.

Yahoo | February 8, 2022

Read More 'RETA' Stories Here

RETA Price Returns

1-mo 6.47%
3-mo -14.54%
6-mo 11.42%
1-year -78.15%
3-year -67.68%
5-year -4.49%
YTD 15.43%
2021 -78.67%
2020 -39.53%
2019 264.40%
2018 98.09%
2017 29.73%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8078 seconds.